Now that the votes are in, the next question is what actually happens next and when. For the complete five-step road map from advisory recommendation to legal compounding access (including the realistic 2027–2028 timeline and the Category 1 wildcard), read The FDA Voted. Now What? The Complete Regulatory Road Map After the PCAC Peptide Decision.
For research and educational purposes only. Not medical advice.
This post is a follow-up to our July 23 coverage of the FDA Pharmacy Compounding Advisory Committee hearings. If readers missed Day 1, the short version is that the committee voted to recommend BPC-157, KPV, TB-500, and MOTS-c for inclusion on the 503A Bulk Drug Substances List by margins of 8–6 across three of the four compounds. Day 2 wrapped on Friday, July 24, 2026, and delivered one surprise in a largely consistent pattern.
TL;DR: Day 2 Final Results: Semax and Epitalon (Epithalon) Approved, Emideltide Rejected
The FDA advisory committee voted to recommend Semax and Epitalon for compounding pharmacy access and voted against Emideltide. That brings the final two-day score to 6 out of 7 peptides recommended for inclusion on the 503A list, with Emideltide being the only compound that did not make it through. As with Day 1, these recommendations are non-binding. The FDA makes the final call. A rulemaking process must follow before anything changes at a pharmacy. The realistic timeline for access remains 2027 for most of these compounds.
The Day 2 PCAC Votes: Semax, Epitalon, and Emideltide
Semax PCAC Vote: 8–5 In Favor. Recommended for Compounding
Semax received the strongest majority of Day 2 and one of the strongest of the entire two-day meeting. The committee voted 8–5 to recommend Semax for inclusion on the 503A Bulk Drug Substances List for the treatment of cerebral ischemia, migraine, and trigeminal neuralgia.
This result carries particular weight because Semax has the most developed evidence base of the three Day 2 compounds. It has been an approved prescription pharmaceutical in Russia since the late 1990s for stroke and cognitive disorders. Over 100 peer-reviewed publications document its mechanism, which centers on BDNF upregulation, melanocortin receptor activation, and neuroprotection across multiple CNS applications. The committee appeared to weigh that body of evidence, combined with Semax's decades of clinical use history outside the United States, more heavily than the FDA career scientists who recommended against it.
The FDA staff's concern with Semax included a signal related to amphetamine potentiation and anticoagulant properties that appeared in some studies. The majority of the committee did not find these signals sufficient to outweigh the case for compounding access. For a deeper look at Semax's research profile, see our nootropic peptide guide covering Semax, Selank, and related compounds.
Epitalon PCAC Vote: 7–5 (1 Abstention). Recommended for Compounding
Epitalon, the synthetic tetrapeptide developed from the pineal gland research of Dr. Vladimir Khavinson, was recommended for inclusion for the treatment of insomnia. The vote was 7–5 with one abstention, the narrowest margin of any favorable recommendation across the two-day meeting.
What makes this vote significant beyond the numbers: the FDA's own briefing documents had specifically flagged Epitalon's telomerase activation as a potential safety concern due to theoretical carcinogenicity implications. The committee voted to recommend it anyway, reflecting a judgment that the available evidence on Epitalon's safety profile, combined with its decades of use in Russian clinical practice and the 2025 independent Western laboratory replications confirming the telomerase mechanism, provided sufficient basis for a compounding pathway recommendation.
The narrow margin is worth acknowledging. A 7–5 vote with an abstention is not a strong endorsement. It is a majority. The dissenting members citing insufficient safety data have a legitimate point, and that nuance will likely be relevant when the FDA conducts its own independent review of the committee's recommendation. For full background on Epitalon's research history, see our complete guide to Khavinson peptides.
Emideltide (DSIP) PCAC Vote: 6–7 (1 Abstention). Not Recommended
Emideltide, also known as Delta Sleep-Inducing Peptide, was the one compound across both days that the committee declined to recommend. The vote was 6–7 with one abstention, making it the narrowest outcome of the entire proceeding in either direction.
Emideltide was proposed for the treatment of insomnia, narcotic dependence, and opioid withdrawal. The committee's concerns centered on two issues that proved decisive. First, the lack of reliable human clinical evidence for the specific proposed routes and indications. Emideltide has the longest research history of the seven compounds, having been studied since its isolation in 1977, but the available human evidence remains limited and inconsistently documented by modern clinical trial standards. Second, purity data concerns. FDA scientists raised specific concerns about characterization and quality data for Emideltide that went beyond the characterization concerns raised for other compounds, suggesting that the available information on the substance itself was insufficient to support a compounding recommendation at this time.
The irony of Emideltide's rejection is not lost on the research community. The compound with the longest research history of the seven was the only one the committee turned down. The reasons are instructive: decades of research are not the same as well-characterized, well-controlled human evidence in the formats the 503A framework requires.
Complete Two-Day PCAC Scorecard: All 7 Peptide Votes
Here is the complete picture of where all seven compounds landed across the two-day meeting.
| Compound | Vote | Result | Indication |
|---|---|---|---|
| BPC-157 | 8–6 (1 abstention) | Recommended | Wound healing, gastrointestinal |
| KPV | 8–6 (1 abstention) | Recommended | Inflammatory conditions, ulcerative colitis |
| TB-500 | 8–6 (1 abstention) | Recommended | Wound healing, tissue repair |
| MOTS-c | 7–5 | Recommended | Obesity-related metabolic applications |
| Semax | 8–5 | Recommended | Cerebral ischemia, migraine, trigeminal neuralgia |
| Epitalon | 7–5 (1 abstention) | Recommended | Insomnia |
| Emideltide (DSIP) | 6–7 (1 abstention) | Not Recommended | Insomnia, narcotic dependence, opioid withdrawal |
Six out of seven. The only compound that did not receive a favorable recommendation was the one with the most specific characterization and purity data concerns, not the one with the least research history overall.
Why the Votes Broke the Way They Did
The consistent 8–6 and 7–5 vote margins across most of Day 1 were not coincidental. The voting pattern reflected a committee that was internally split along a clear philosophical divide.
The majority favored a harm-reduction and access argument: that these compounds have demonstrated enough evidence of plausible benefit and acceptable safety that restricting them to the unregulated gray market, where there is no quality oversight, no physician involvement, and no documentation, creates more risk than regulated compounding access would. Secretary Kennedy's public framing of the 2023 restrictions as having created the gray market resonated with the majority position.
The dissenting members, primarily physician representatives and consumer safety advocates, consistently argued that a favorable committee vote could be misinterpreted by the public as an endorsement of efficacy, that the lack of well-controlled human clinical trials creates genuine uncertainty about safety in uncharacterized patient populations, and that the committee was being asked to recommend access to compounds whose chemical characterization is still insufficiently defined by pharmaceutical standards.
One dissenting voice from Dr. Friedhelm Sandbrink, national program director for pain management in the Veterans Health Administration, captured the minority position clearly: "I don't think we can skip the rigorous scientific studies that are needed when we endorse any kind of product and make it available."
Both positions reflect genuine and legitimate concerns. The majority voted the way they did. The FDA now has to decide what it does with six favorable recommendations and one rejection from a committee that voted against its own career scientists' recommendation across nearly every compound.
A detail worth flagging that has received relatively little coverage: the committee's composition was specifically noted as including multiple members appointed during the Kennedy era who have affiliations with peptide-providing clinics. HHS maintained these members passed standard ethics review and any disqualified candidates were removed. That context is part of the public record and is relevant to how the FDA will weigh the committee's recommendations in its independent review.
The Political Dimension: Kennedy, the FDA, and the Gray Market Argument
It would be inaccurate to cover these votes without acknowledging that they did not take place in a political vacuum. HHS Secretary Kennedy has publicly championed broader access to these compounds from the moment he took office, framing the 2023 restrictions as having created the gray market that drives unsafe sourcing. The April 2026 removal of 12 peptides from Category 2, which set up these hearings, came from his office.
The committee's votes align with Kennedy's stated policy position. That does not make them wrong. It means the FDA, in conducting its independent review of the recommendations, will need to weigh the scientific record on its own merits rather than simply adopting the committee's conclusions. That independent review, and the rulemaking process that follows, is where the regulatory story actually gets resolved.
What Happens Next: Timeline and What It Means for Researchers
What is the FDA's next step after the PCAC votes?
The FDA will review the committee's recommendations and issue its own final determinations. It can accept or reject individual recommendations independently. A compound the committee recommended could be declined. A compound the committee rejected could in theory be reconsidered through other mechanisms, though Emideltide's path to the 503A list now faces a significant additional obstacle.
When will these peptides be available through compounding pharmacies?
Once the FDA issues a determination to add a compound to the 503A list, notice-and-comment rulemaking follows. That process typically takes 8 to 12 months. The realistic timeline for any of these compounds becoming legally available through licensed compounding pharmacies with valid prescriptions is late 2026 at the absolute earliest and 2027 for most.
Do the PCAC votes affect gray market research vendors?
No. The gray market is unaffected in either direction by these votes. Research-use-only vendors operate entirely outside the 503A compounding framework. The committee votes are about the licensed compounding pharmacy pathway. They change nothing about the current sourcing landscape for researchers who access peptides through research channels.
Does a positive vote mean the peptides are now safe or endorsed?
No. Quality still matters as much as it did before the meeting. A committee vote to recommend a compound for compounding does not improve the quality of what is currently on the market through research channels. The same COA verification standards, the same vendor vetting criteria, and the same sourcing discipline apply today that applied before the first vote was cast on July 23.
What the two-day meeting did accomplish is move six specific peptides meaningfully closer to a legitimate, physician-supervised, pharmacy-quality access pathway that the research community has not had since the 2023 restrictions. That matters, and it is genuinely good news for anyone who cares about quality and safety in this space.
The next PCAC meeting, scheduled before the end of February 2027, will evaluate GHK-Cu (injectable form), PEG-MGF, Melanotan II, DiHexa, and LL-37. We will cover that meeting as it approaches.
For current coupon codes, vetted vendor information, and ongoing regulatory updates, visit RUO Codes.
For research and educational purposes only. Not medical advice. Research peptides are not FDA-approved for human use. Regulatory status may change as the FDA conducts its independent review of the PCAC recommendations.